Common Warts (Verruca Vulgaris)
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
Verrica PharmaceuticalsCantharidin
Verrica PharmaceuticalsCantharidin
Nielsen BioSciencesCandin, Intradermal Solution
Clinical Trials (3)
Total enrollment: 1,230 patients across 3 trials
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Start: Jun 2026Est. completion: Oct 2027300 patients
Phase 3Not Yet Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Start: Mar 2026Est. completion: May 2028600 patients
Phase 3Recruiting
Candin for the Treatment of Common Warts
Start: Jan 2025Est. completion: Aug 2025330 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,230 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.